Learning from ‘big data’: compounds and targets

• ‘Big data’ provide challenges and opportunities for pharmaceutical R&D.
• Currently available compound activity data and target annotations have ‘big data’ character.
• Achieving compound data completeness is an elusive goal.
• Extraction of knowledge from ‘big compound data’ is a must and does not depend on data completeness.